Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Expression of HER2 in the eye and the potential for on-target side effects with antibody-drug conjugates.
Journal: Scientific reports
Published: December 19, 2025
A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma.
Journal: Clinical colorectal cancer
Published: October 02, 2015
A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 20, 2014
Phase II study of PX-866 in recurrent glioblastoma.
Journal: Neuro-oncology
Published: October 16, 2014
A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: June 14, 2014
A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.
Journal: Investigational new drugs
Published: April 28, 2014
Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic.
Journal: Journal of clinical and translational hepatology
Published: August 30, 2013
A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours.
Journal: British journal of cancer
Published: April 30, 2013
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.
Journal: Molecular oncology
Published: March 07, 2013
A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 14, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026